MX2019012433A - Identificacion, fabricacion y uso de neoantigenos. - Google Patents

Identificacion, fabricacion y uso de neoantigenos.

Info

Publication number
MX2019012433A
MX2019012433A MX2019012433A MX2019012433A MX2019012433A MX 2019012433 A MX2019012433 A MX 2019012433A MX 2019012433 A MX2019012433 A MX 2019012433A MX 2019012433 A MX2019012433 A MX 2019012433A MX 2019012433 A MX2019012433 A MX 2019012433A
Authority
MX
Mexico
Prior art keywords
methods
manufacture
systems
disclosed
tumor
Prior art date
Application number
MX2019012433A
Other languages
English (en)
Inventor
Yelensky Roman
Bulik-Sullivan Brendan
Busby Jennifer
Boucher Thomas
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of MX2019012433A publication Critical patent/MX2019012433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/40—Encryption of genetic data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioethics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Se describe en la presente un sistema y métodos para determinar los alelos, neoantígenos y una composición de vacuna según se determina en función de las mutaciones tumorales de un individuo. También se describen sistemas y métodos para obtener datos de secuenciación de alta calidad a partir de un tumor. Además, se describen en la presente sistemas y métodos para identificar cambios somáticos en datos de genomas polimórficos. Finalmente, se describen en la presente vacunas únicas contra el cáncer.
MX2019012433A 2017-04-19 2018-04-19 Identificacion, fabricacion y uso de neoantigenos. MX2019012433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487469P 2017-04-19 2017-04-19
PCT/US2018/028438 WO2018195357A1 (en) 2017-04-19 2018-04-19 Neoantigen identification, manufacture, and use

Publications (1)

Publication Number Publication Date
MX2019012433A true MX2019012433A (es) 2019-12-11

Family

ID=63857025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012433A MX2019012433A (es) 2017-04-19 2018-04-19 Identificacion, fabricacion y uso de neoantigenos.

Country Status (14)

Country Link
US (1) US20210113673A1 (es)
EP (1) EP3612965A4 (es)
JP (2) JP7217711B2 (es)
KR (1) KR20190140935A (es)
CN (1) CN110636852A (es)
AU (2) AU2018254526B2 (es)
BR (1) BR112019021782A2 (es)
CA (1) CA3060569A1 (es)
CO (1) CO2019012345A2 (es)
IL (1) IL269855B2 (es)
MX (1) MX2019012433A (es)
RU (1) RU2019136762A (es)
SG (1) SG11201909652WA (es)
WO (1) WO2018195357A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
CN116693695A (zh) 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
JP7307048B2 (ja) * 2017-07-14 2023-07-11 ザ フランシス クリック インスティチュート リミティッド 腫瘍におけるｈｌａアレルの分析及びそれらの使用
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
AU2019205330A1 (en) 2018-01-04 2020-08-27 Iconic Therapeutics Llc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
WO2020041748A1 (en) * 2018-08-24 2020-02-27 The Regents Of The University Of California Mhc-ii genotype restricts the oncogenic mutational landscape
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
CA3119752A1 (en) * 2018-11-07 2020-05-14 Gritstone Oncology, Inc. Alphavirus neoantigen vectors and interferon inhibitors
JP2022516639A (ja) 2019-01-03 2022-03-01 エヴァクシオン・バイオテック・アクティエセルスカブ ネオエピトープを標的とするワクチン
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN113711239A (zh) * 2019-03-06 2021-11-26 磨石生物公司 利用ii类mhc模型鉴别新抗原
US20220184191A1 (en) 2019-03-11 2022-06-16 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
WO2020185010A1 (ko) * 2019-03-12 2020-09-17 (주)신테카바이오 인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법
EP4198513A1 (en) * 2019-05-03 2023-06-21 Epivax Therapeutics, Inc. Neoantigens in cancer
KR20220041844A (ko) * 2019-07-02 2022-04-01 그릿스톤 바이오, 인코포레이티드 Hiv 항원 및 mhc 복합체
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
WO2021048400A1 (en) 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying t-cell epitopes
AU2020407905A1 (en) 2019-12-18 2022-07-28 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
US20230047716A1 (en) * 2020-01-07 2023-02-16 Korea Advanced Institute Of Science And Technology Method and system for screening neoantigens, and uses thereof
AU2021253641A1 (en) 2020-04-07 2022-10-27 Evaxion Biotech A/S Neoepitope immunotherapy with APC targeting unit
JP2023530719A (ja) * 2020-06-18 2023-07-19 パーソナリス，インコーポレイティド 表面提示ペプチドを予測するための機械学習技術
JP2023533871A (ja) 2020-07-14 2023-08-04 エヴァクシオン・バイオテック・アクティエセルスカブ 免疫療法のためのａｐｃ標的化単位
EP4002383A3 (en) 2020-11-13 2022-08-03 Tokyo Institute of Technology Information processing device, information processing method, recording medium recording information processing program, and information processing system
JP7057003B1 (ja) 2021-02-26 2022-04-19 国立大学法人東京工業大学 予測装置、学習済みモデルの生成装置、予測方法、学習済みモデルの生成方法、予測プログラム、及び学習済みモデルの生成プログラム
JP7057004B1 (ja) 2021-03-05 2022-04-19 国立大学法人東京工業大学 予測装置、学習済みモデルの生成装置、予測方法、学習済みモデルの生成方法、予測プログラム、及び学習済みモデルの生成プログラム
WO2022229966A1 (en) 2021-04-29 2022-11-03 Yeda Research And Development Co. Ltd. T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
CN113762416B (zh) * 2021-10-15 2023-05-30 南京澄实生物科技有限公司 基于多模态深度编码的抗原免疫原性预测方法和系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252795B2 (en) * 2010-05-14 2015-09-03 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
EP2983702A2 (en) * 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP4299136A3 (en) * 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス （アイピー） カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム

Also Published As

Publication number Publication date
CN110636852A (zh) 2019-12-31
AU2018254526A1 (en) 2019-11-14
JP7217711B2 (ja) 2023-02-03
IL269855B2 (en) 2023-05-01
SG11201909652WA (en) 2019-11-28
JP2020519246A (ja) 2020-07-02
IL269855A (en) 2019-11-28
CA3060569A1 (en) 2018-10-25
AU2018254526B2 (en) 2024-02-15
EP3612965A4 (en) 2021-01-13
CO2019012345A2 (es) 2020-01-17
US20210113673A1 (en) 2021-04-22
JP2023055775A (ja) 2023-04-18
RU2019136762A (ru) 2021-05-19
KR20190140935A (ko) 2019-12-20
AU2024202903A1 (en) 2024-05-23
WO2018195357A1 (en) 2018-10-25
IL269855B1 (en) 2023-01-01
EP3612965A1 (en) 2020-02-26
BR112019021782A2 (pt) 2020-08-18

Similar Documents

Publication Publication Date Title
MX2019012433A (es) Identificacion, fabricacion y uso de neoantigenos.
PH12018501267A1 (en) Neoantigen identification, manufacture, and use
WO2020023420A3 (en) Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
MX2018010362A (es) Metodos y sistemas para evaluar carga mutacional de tumores.
PH12019502518A1 (en) Alphavirus neoantigen vectors
MX2018011941A (es) Sistema de analisis de variantes geneticas y fenotipos y sus metodos de uso.
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
GB2552267A (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
NZ745327A (en) Whole-cell cancer vaccines and methods for selection thereof
GB2573663A (en) Viral methods of making genetically modified cells
MY202410A (en) Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2017015210A (es) Composiciones y metodos para el cribado de tumores solidos.
BR112017015888A2 (pt) dispositivo, adesivo de eletromiografia, e método para determinar e/ou monitorar o esforço respiratório de um indivíduo; e programa de computador
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
MX2018013744A (es) Metodos para clasificar pacientes con un cancer solido.
MX2022012384A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
WO2020132499A3 (en) Systems and methods for using fragment lengths as a predictor of cancer
WO2018234506A3 (en) PERSONALIZED VACCINE
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
MX2022001879A (es) Metodos de evaluacion genomica en ganado.
MX2018014973A (es) Combinaciones farmaceuticas.
WO2015153948A3 (en) Microtentacle imaging in patient tumor samples
MX2019012260A (es) Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.
MA39203A1 (fr) Typage de hla à haute résolution